About Altimmune
Altimmune (NASDAQ:ALT) is a clinical-stage biopharmaceutical company focused on developing treatments that address critical needs in respiratory diseases and immune-modulating therapies. Their operations span the discovery, development, and commercialization of novel products to improve the lives of patients suffering from a range of conditions including obesity, liver diseases, and COVID-19. One of their flagship projects is a vaccine aimed at providing long-lasting protection against influenza, showcasing their commitment to tackling global health challenges. With a strategic approach to innovation and a dedicated team, Altimmune aims to advance its pipeline of promising candidates through the clinical stages, continually seeking to expand its impact on public health worldwide.
Snapshot
Operations
Products and/or services of Altimmune
- HepTcell, a therapeutic vaccine candidate for the treatment of chronic hepatitis B.
- AdCOVID, a single-dose intranasal vaccine candidate for COVID-19.
- T-COVID, an intranasal immunomodulator treatment for early COVID-19.
- ALT-801, a novel GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic steatohepatitis (NASH).
- NasoShield, an anthrax vaccine candidate administered through a single intranasal dose.
- NasoVAX, an intranasal influenza vaccine candidate designed to provide long-lasting protection.
Altimmune executive team
- Dr. M. Scot Roberts Ph.D.Chief Scientific Officer
- Mr. Jerome Benedict DursoChairman, CEO & President
- Mr. Gregory L. Weaver CPA, M.B.A.Chief Financial Officer
- Mr. Andrew Shutterly M.S.Principal Financial & Accounting Officer and Corporate Controller
- Mr. Bertrand Georges Ph.D.Chief Technology Officer
- Mr. Tony Blandin B.S.Vice President of Quality & Compliance Management
- Ms. Robin E. Abrams J.D.General Counsel & Chief Legal Officer
- Mr. Raymond M. Jordt M.B.A.Chief Business Officer
- Ms. Linda M. RichardsonChief Commercial Officer
- Dr. Christophe Arbet-Engels M.B.A., M.D., Ph.D.Chief Medical Officer